Ambry Genetics, now a wholly owned subsidiary of Tempus AI (TEM), announced an enhancement to the Ambry CARE Program, Ambry’s digital platform that streamlines cancer risk assessment and genetic testing workflows. The update integrates breast density into the Tyrer-Cuzick breast cancer risk score within the electronic health record, providing clinicians with more precise and personalized risk estimates at the point of care that can guide recommendations for breast cancer screening and risk reduction, the company said in a statement.
Claim 30% Off TipRanks
Trade TEM with leveragePublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Short Report: Tempus AI short interest reaches record high
- Tempus AI price target raised to $95 from $80 at Guggenheim
- Cathie Wood Offloads AMD Stock, Boosts Holdings in Alibaba and Baidu
- Cathie Wood Continues Selling Tempus AI and Roku Shares
- Why Is Tempus AI Stock (TEM) Rising in Premarket Trading Today?